News 2025-11-18
Porton Improves in the 2025 S&P Global ESG Score
Porton Pharma Solutions Ltd. (hereinafter “Porton”) is glad to announce that it scored 50 in the 2025 S&P Global Corporate Sustainability Assessment reflecting an improvement of 6 points over the previous assessment, where scores in all the three dimensions getting improved (ESG Score as of 12/11/2025).
In this year’s assessment, Porton’s scores in Environmental, Social and Governance & Economic dimensions increase by 12, 5, and 3 points respectively. Notable progress was made in criteria such as Energy, Waste & Pollutants, Water, Climate Strategy, and Supply Chain Management.
Adhering to the ESG concepts of "Green Development, Promote Common Progress, build a Healthy Society, and Enhance Corporate Governance", Porton is committed to integrating ESG into its corporate strategy and operations, and continuously strengthens the management of material issues.
In 2025, Porton further enhanced its ESG management through various measures. At the commitment level, our carbon reduction target has been verified by the SBTi, and we also released environmental targets covering three major areas of energy, water resources and waste management. At the management system level, we formulated Supplier Code of Conduct to further promote supply chain management. At the personnel capability level, we organized trainings on carbon verification and sustainable supply chain to improve employees’ professional skills.
Looking ahead, Porton will continue to practice the ESG development concept and promote sustainable development.
Others
More
News 2026-10-16
Porton Achieves Third-Party Verification for Its First Commercial Product LCA and PCF Study
Conducted in accordance with ISO 14040:2006 and ISO 14044:2006 (Life Cycle Assessment) and ISO 14067:2018 (Product Carbon Footprint) standards, the study employs a cradle-to-gate system boundary, marking the formal extension of Porton's ESG management from the organizational level to the product level.

News 2026-10-09
Porton Successfully Concludes CPHI Milan 2026, Showcasing Integrated CDMO Capabilities and Connecting for Global Pharma Innovation
Porton Pharma Solutions showcased its capabilities at the event, engaging in multiple face-to-face meetings with pharmaceutical and biotech companies and industry partners from Europe and around the world at Booth 10K6, discussing drug development trends, supply chain challenges, and diverse CDMO collaboration opportunities.